Dr. Thomas Hecht and Dr. Mathieu Simon join the Board; Dr. Hecht appointed Chairman

Sunstone Life Science Ventures Fund II portfolio company VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced the election of Thomas Hecht, MD, and Mathieu Simon, MD, as new members to its Board of Directors. In addition, Dr. Hecht has been appointed as Chairman of the Board, taking over from Dr. Klaus Breiner, who will continue his role in the company as Vice-Chairman.